Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.

The objective of this randomized trial was to compare two methods of re-irradiation in terms of toxicity and survival. PATIENTS AND METHODS: Patients with recurrence/second primary in previously irradiated area were randomly allocated to receive either 60 Gy over 11 weeks with concomitant 5FU - hydroxyurea (VP-arm), or 60 Gy (1.2 Gy twice daily) over 5 weeks with cetuximab (HFR-arm). Primary endpoint was treatment interruption>15 days (acute toxicity). RESULTS: Twenty-six patients were included in VP-arm and 27 in HFR-arm. One patient in VP-arm experienced>15 days interruption due to toxicity, and none in HFR-arm. In both arms, all patients received at least 60 Gy. In VP-arm, 8/26 patients had chemotherapy delay and/or dose reduction. In HFR-arm, 4/27 patients had
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research

Related Links:

AbstractIn patients with locally advanced human papillomavirus (HPV)-unrelated head and neck squamous-cell carcinoma (HNSCC), cisplatin and radiation therapy (CisRT) resulted in a local –regional recurrence (LRR) rate of 35%, progression-free survival (PFS) of 49%, and overall survival (OS) of 60%. We, and others, showed thatnab-paclitaxel is an active agent in metastatic and locally advanced HNSCC. The aim of this report was to assess the efficacy ofnab-paclitaxel-based induction chemotherapy and CisRT in HPV-unrelated HNSCC. We performed a retrospective single-institution analysis of patients treated withnab-paclit...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundAdding concurrent chemotherapy (CTx) to definitive radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) improves overall survival. A  comparable effect has been reported for hyperfractionated radiotherapy (HFX-RT) alone. Adding concurrent CTx to HFX-RT has been investigated in multiple trials, yet an evident effect on oncological outcomes and toxicity profile has not been established to date. Thus, the aim of the current study w as to perform a meta-analysis on the clinical outcome and toxicity of the addition of CTx to HFX-RT.Patients and met...
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
ConclusionsA single-cycle induction chemotherapy for HNSCC enables surgery plus adjuvant therapy as well as chemoradiotherapy. The long-term local and distant disease control was good but varied between tumors in the larynx and mesopharynx/tongue vs. hypopharynx.
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
ConclusionsFU-FDG-PET/CT in real-life has a high NPV and significant prognostic value. However, false-positive scans induce invasive procedures in a significant fraction of patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAdjuvant nivolumab after salvage surgery in HNSCC patients is safe however, increased enrollment is required to establish efficacy.Clinical trial identificationNCT03355560.Legal entity responsible for the studyTrisha Wise-Draper.FundingBMS.DisclosureT. Wise-Draper: Research grant / Funding (self): BMS; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Merck; Research grant / Funding (institution): Tesaro. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAt lower expression levels, CPS detects a larger fraction of responders than TPS while maintaining similar survival results. At higher expression levels, CPS ≥50 can be used interchangeably with TPS ≥50%. Thus, CPS is a valid scoring method for determining PD-L1 status in patients with HNSCC being evaluated for second-line treatment. Efficacy results demonstrating treatment benefit with pembrolizumab compared with SOC were similar regardless of scori ng method used.Clinical trial identificationNCT02252042.Editorial acknowledgementHolly C. Cappelli, PhD, and Dana Francis, PhD, of the ApotheCom pembrolizumab...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsERCC1 expression is a well-established biomarker for cisplatin resistance. Our study demonstrates that wtHRASov tumours represent a distinctive entity that strongly express ERCC1 and can be resensitized to cisplatin by tipifarnib.Legal entity responsible for the studyThe authors.FundingKura Oncology.DisclosureT. Rampias: Research grant / Funding (institution): Kura Oncology Company. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsP vs E showed favorable OS in Asia and non-Asia subgrps, regardless of PD-L1 status; responses were durable, particularly among all non-Asia subgrps; safety was favorable. P+C vs E showed favorable OS in pts with CPS ≥20 in Asia and non-Asia subgrps regardless of PD-L1 status, durable responses, and similar safety.Clinical trial identificationNCT02358031.Editorial acknowledgementDoyel Mitra, PhD, and Dana Francis, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA), funded by Merck Sharp&Dohme Corp., a subsidiary of Merck&Co., Inc., Kenilworth, NJ, USA.Legal entity responsible for the studyMer...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundLA-HNSCC is treated with concurrent chemo-radiation. Majority of guidelines recommend bolus Cisplatin in the dose of 100  mg/m2 (on days 1, 22, and 43). The meta-analysis reported by MACH-NC group found a greater benefit for platinum-based chemotherapy as compared with other protocols. Multiple studies back this notion. Other options are weekly cisplatin (30-40  mg/m2) or split course radiation and combination of DDP+5FU. Alternative dosing schedules (e.g., 30 to 40 mg/m2 weekly, 6 mg/m2 daily, or 20 mg/m2 daily for five days weeks 1 and 5) are used because of improved p...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
BACKGROUND: This prospective multicenter study evaluated the prognostic value of circulating tumor cells (CTCs) in relapsing nonoperable or metastatic head and neck squamous cell carcinoma (rHNSCC) treated by chemotherapy and cetuximab. METHODS: In 65 patients suitable for analyses, peripheral blood was taken at day 0 (D0) D7, and D21 of treatment for CTC detection by CellSearch®, EPISPOT, and flow cytometry (FCM). Progression-free survival (PFS) was assessed with the Kaplan–Meier method and compared with the log-rank test (P
Source: Clinical Chemistry - Category: Chemistry Authors: Tags: Cancer Diagnostics (since 2002) Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Erbitux | HNSCC | Radiology | Skin Cancer | Squamous Cell Carcinoma | Toxicology